Skip to main content

Table 2 Univariate and multivariate analyses of clinical parameters on disease-free survival and overall survival

From: Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma

Factor Univariate analysis Multivariate analysis
HR (log rank) 95% CI P value HR (log rank) 95% CI P value
Disease-free survival
 Sex (female/male) 0.818 0.416–1.606 0.559    
 Age (≥ 65/< 65) 1.030 0.742–1.429 0.862    
 Smoking (yes/no) 0.892 0.632–1.257 0.513    
 PS (≥ 1/0) 1.092 0.759–1.571 0.636    
 Stage (II–III/I) 1.425 1.028–1.973 0.033 1.614 1.156–2.255 0.005
 Pleural invasion (yes/no) 1.629 0.900–2.950 0.107    
 Vascular invasion (yes/no) 1.674 0.819–3.420 0.158    
 Differentiation (high/non-high) 1.080 0.505–2.309 0.842    
 PD-L1 (positive/negative) 0.702 0.474–1.041 0.141    
 CD8+ TIL (positive/negative) 0.632 0.444–0.898 0.010 0.711 0.429–1.180 0.187
 TMB (> median/≤ median) 1.454 1.047–2.019 0.040 1.122 0.652–1.929 0.677
 PD-L1 negative and TMB > median VS. others 1.533 1.097–2.140 0.021 1.176 0.708–1.954 0.530
 PD-L1 negative and TMB ≤ median VS. others 0.884 0.633–1.235 0.470    
 PD-L1 positive and TMB ≤ median VS. others 0.506 0.272–0.938 0.031 0.506 0.261–0.979 0.043
 PD-L1 positive and TMB > median VS. others 0.972 0.611–1.544 0.903    
 CD8+ TIL negative and TMB > median VS. others 2.224 1.405–3.520 0.005 1.416 0.695–2.888 0.338
 CD8+ TIL negative and TMB ≤ median VS. others 1.102 0.705–1.720 0.670    
 CD8+ TIL positive and TMB ≤ median VS. others# 0.629 0.441–0.898 0.011    
 CD8+ TIL positive and TMB > median VS. others 1.070 0.767–1.495 0.689    
Overall survival
 Sex (female/male) 1.012 0.317–3.229 0.984    
 Age (≥ 65/< 65) 1.252 0.758–2.068 0.381    
 Smoking (yes/no) 1.038 0.604–1.785 0.892    
 PS (≤ 1/0) 0.995 0.562–1.761 0.987    
 Stage (II–III/I) 2.952 1.685–5.172 < 0.001 2.844 1.606–5.038 < 0.001
 Pleural invasion (yes/no) 1.425 0.613–3.309 0.411    
 Vascular invasion (yes/no) 2.214 0.886–5.534 0.089 1.660 0.646–4.268 0.293
 Differentiation (high/non-high) 1.892 0.758–4.727 0.172    
 PD-L1 (positive/negative) 0.701 0.373–1.318 0.270    
 CD8+ TIL (positive/negative) 0.825 0.476–1.430 0.493    
 TMB (> median/≤ median) 1.366 0.824–2.263 0.227    
 PD-L1 negative and TMB > median VS. others 1.591 0.960–2.638 0.100 1.425 0.822–2.468 0.207
 PD-L1 negative and TMB ≤ median VS. others 0.818 0.485–1.380 0.452    
 PD-L1 positive and TMB ≤ median VS. others 0.707 0.283–1.765 0.457    
 PD-L1 positive and TMB > median VS. others 0.753 0.343–1.656 0.481    
 CD8+ TIL negative and TMB > median VS. others 1.785 0.929–3.341 0.078 1.652 0.811–3.364 0.166
 CD8+ TIL negative and TMB ≤ median VS. others 0.753 0.343–1.654 0.480    
 CD8+ TIL positive and TMB ≤ median VS. others 0.819 0.480–1.398 0.464    
 CD8+ TIL positive and TMB > median VS. others 1.031 0.614–1.730 0.909    
  1. HR hazard ratio, CI confidence interval, PS performance score, TMB tumor mutation burden
  2. #Reduction of degrees of freedom due to constants or linear dependent variables